{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Green cardamom", "Nonalcoholic fatty liver disease", "Obesity", "Overweight", "Protocol", "Trial"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "28592311", "DateCompleted": {"Year": "2018", "Month": "05", "Day": "16"}, "DateRevised": {"Year": "2023", "Month": "11", "Day": "12"}, "Article": {"ArticleDate": [{"Year": "2017", "Month": "06", "Day": "07"}], "Language": ["eng"], "ELocationID": ["260", "10.1186/s13063-017-1979-3"], "Journal": {"ISSN": "1745-6215", "JournalIssue": {"Volume": "18", "Issue": "1", "PubDate": {"Year": "2017", "Month": "Jun", "Day": "07"}}, "Title": "Trials", "ISOAbbreviation": "Trials"}, "ArticleTitle": "The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial.", "Pagination": {"StartPage": "260", "MedlinePgn": "260"}, "Abstract": {"AbstractText": ["The relationship between dietary components and nonalcoholic fatty liver disease (NAFLD) needs to be further investigated. The potential health benefits of cardamom have been found in some studies. Cardamom showed beneficial effect on hepatomegaly, dyslipidemia, and fasting hyperglycemia in animals. However, some adverse effects of cardamom have been reported in animals. No previous human study had been conducted on the effects of cardamom in NAFLD. This study aims to determine the effects of green cardamom (Elettaria cardamomum) supplementation on blood glucose indices, lipids, inflammatory profiles, and liver function, especially by examining irisin, paraxonase-1 (PON1) and sirtuin-1 (Sirt1) in obese patients with NAFLD.", "This trial is to be conducted at the polyclinic of the National Iranian Oil Company (NIOC) Central Hospital, Tehran. Eighty obese patients with NAFLD will be selected according to the eligibility criteria. The NAFLD diagnosis method is ultrasonography. Patients will be randomly divided into two groups by a random-number table (cardamom and placebo groups, two 500-mg capsules, three times/day, taken with meals for 3\u00a0months, follow-up monthly). General characteristics, dietary intakes (at the beginning, middle, and end), and physical activity (at the beginning and end) will be assessed using a general, 24-h food recall, and short-form International Physical Activity Questionnaires (IPAQ), respectively. Lifestyle advice will be presented to both groups identically. At the beginning and the end, anthropometrics (weight, height, and waist circumference), blood pressure, extent of fatty liver, and blood biomarkers, including serum glucose indices (fasting blood sugar (FBS)) and insulin (FBI), homeostasis model assessment-insulin resistance (HOMA-IR), Quantitative Insulin Sensitivity Check Index (QUICKI)), lipids (triglyceride (TG), low-density lipoprotein-cholesterol (LDL-c), high-density lipoprotein-cholesterol (HDL-c), total cholesterol (TC)), inflammatory markers (highly sensitive C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-\u03b1), interleukin-6 (IL-6)), liver enzymes (alanine transaminase (ALT), aspartate transaminase (AST)), irisin, PON1, and Sirt1, will be determined.", "This trial would be the first to assess the effects of green cardamom on several blood factors, including glucose indices, lipids, inflammatory markers, liver enzymes, irisin, PON1, and Sirt1, and blood pressure and anthropometry in obese patients with NAFLD. Further study of cardamom's potential in improving NAFLD is suggested.", "Iranian Registry of Clinical Trials (IRCT), ID number: IRCT2015121317254N4 . Registered on 27 December 2015."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Daneshi-Maskooni", "ForeName": "Milad", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran. s_akeshavarz@yahoo.com."}], "LastName": "Keshavarz", "ForeName": "Seyed Ali", "Initials": "SA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "National Iranian Oil Company (NIOC) Central Hospital, Tehran, Iran."}], "LastName": "Mansouri", "ForeName": "Siavash", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran."}], "LastName": "Qorbani", "ForeName": "Mostafa", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Baqiyatallah University of Medical Sciences, Tehran, Iran."}], "LastName": "Alavian", "ForeName": "Seyed Moayed", "Initials": "SM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Badri-Fariman", "ForeName": "Mahtab", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Jazayeri-Tehrani", "ForeName": "Seyed Ali", "Initials": "SA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran. gsotodeh@tums.ac.ir."}], "LastName": "Sotoudeh", "ForeName": "Gity", "Initials": "G"}], "DataBankList": [{"DataBankName": "ISRCTN", "AccessionNumberList": ["IRCT2015121317254N4"]}], "PublicationTypeList": ["Journal Article", "Randomized Controlled Trial", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Trials", "NlmUniqueID": "101263253", "ISSNLinking": "1745-6215"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Biomarkers"}, {"RegistryNumber": "0", "NameOfSubstance": "Blood Glucose"}, {"RegistryNumber": "0", "NameOfSubstance": "FNDC5 protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "Fibronectins"}, {"RegistryNumber": "0", "NameOfSubstance": "Inflammation Mediators"}, {"RegistryNumber": "0", "NameOfSubstance": "Lipids"}, {"RegistryNumber": "0", "NameOfSubstance": "Plant Extracts"}, {"RegistryNumber": "EC 3.1.8.1", "NameOfSubstance": "Aryldialkylphosphatase"}, {"RegistryNumber": "EC 3.1.8.1", "NameOfSubstance": "PON1 protein, human"}, {"RegistryNumber": "EC 3.5.1.-", "NameOfSubstance": "SIRT1 protein, human"}, {"RegistryNumber": "EC 3.5.1.-", "NameOfSubstance": "Sirtuin 1"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": ["blood"], "DescriptorName": "Aryldialkylphosphatase"}, {"QualifierName": ["blood"], "DescriptorName": "Biomarkers"}, {"QualifierName": ["drug effects", "metabolism"], "DescriptorName": "Blood Glucose"}, {"QualifierName": ["drug effects"], "DescriptorName": "Blood Pressure"}, {"QualifierName": [], "DescriptorName": "Clinical Protocols"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Dietary Supplements"}, {"QualifierName": [], "DescriptorName": "Double-Blind Method"}, {"QualifierName": ["chemistry"], "DescriptorName": "Elettaria"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": ["blood"], "DescriptorName": "Fibronectins"}, {"QualifierName": [], "DescriptorName": "Health Status"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["blood"], "DescriptorName": "Inflammation Mediators"}, {"QualifierName": [], "DescriptorName": "Iran"}, {"QualifierName": ["blood"], "DescriptorName": "Lipids"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Middle Aged"}, {"QualifierName": ["blood", "diagnosis", "drug therapy", "physiopathology"], "DescriptorName": "Non-alcoholic Fatty Liver Disease"}, {"QualifierName": ["blood", "diagnosis", "drug therapy", "physiopathology"], "DescriptorName": "Obesity"}, {"QualifierName": [], "DescriptorName": "Phytotherapy"}, {"QualifierName": ["adverse effects", "isolation & purification", "therapeutic use"], "DescriptorName": "Plant Extracts"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "Research Design"}, {"QualifierName": ["blood"], "DescriptorName": "Sirtuin 1"}, {"QualifierName": [], "DescriptorName": "Time Factors"}, {"QualifierName": [], "DescriptorName": "Treatment Outcome"}]}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Sherlock S, Dooley J. Diseases of the liver and biliary system. 11. Oxford: Blackwell Science; 2002. p. 423."}, {"Citation": "Adibi A, Jaberzadeh-Ansari M, Dalili AR, Omidifar N, Sadeghi M. Association between nonalcoholic fatty liver disease (NAFLD) and coronary artery disease (CAD) in patients with angina pectoris. Open J Med Imaging. 2013;3:97\u2013101. doi: 10.4236/ojmi.2013.33015.", "ArticleIdList": ["10.4236/ojmi.2013.33015"]}, {"Citation": "Amirkalali B, Poustchi H, Keyvani H, Khansari MR, Ajdarkosh H, Maadi M, Sohrabi MR, Zamani F. Prevalence of non-alcoholic fatty liver disease and its predictors in north of Iran. Iran J Public Health. 2014;43(9):1275\u201383.", "ArticleIdList": ["PMC4500430", "26175982"]}, {"Citation": "Bagheri Lankarani K, Ghaffarpasand F, Mahmoodi M, Lotfi M, Zamiri N, Heydari ST, Fallahzadeh MK, Maharlouei N, Babaeinejad M, Mehravar S, Geramizadeh B. Non alcoholic fatty liver disease in Southern Iran: a population based study. Hepat Mon. 2013;13(5):e9248. doi: 10.5812/hepatmon.9248.", "ArticleIdList": ["10.5812/hepatmon.9248", "PMC3734894", "23922564"]}, {"Citation": "Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic and clinical implications. Hepatology. 2010;51(2):679\u201389. doi: 10.1002/hep.23280.", "ArticleIdList": ["10.1002/hep.23280", "PMC3575093", "20041406"]}, {"Citation": "Sahebkar A. Potential efficacy of ginger as a natural supplement for nonalcoholic fatty liver disease. World J Gastroenterol. 2011;17(2):271\u20132. doi: 10.3748/wjg.v17.i2.271.", "ArticleIdList": ["10.3748/wjg.v17.i2.271", "PMC3020385", "21246004"]}, {"Citation": "McCullough A. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis. 8(3):521\u201333. doi:10.1016/j.cld.2004.04.004.", "ArticleIdList": ["15331061"]}, {"Citation": "Musso G, Molinaro F, Paschetta E, Gambino R, Cassader M. Lipid modifiers and NASH: statins, ezetimibe, fibrates, and other agents. In; McCullough AJ, Day CP, editors. Non-alcoholic fatty liver disease. Wiley Blackwell; 2013. p. 293\u2013307. http://onlinelibrary.wiley.com/doi/10.1002/9781118556153.ch26/pdf.", "ArticleIdList": ["10.1002/9781118556153.ch26/pdf"]}, {"Citation": "Gaharwar R, Trikha S, Margekar SL, Jatav OP, Ganga PD. Study of clinical profile of patients of non alcoholic fatty liver disease and its association with metabolic syndrome. J Assoc Physicians India. 2015;63(1):12\u20136.", "ArticleIdList": ["26591121"]}, {"Citation": "National Guideline Centre (UK). Non-alcoholic fatty liver disease: assessment and management. London: (NICE Guideline, No. 49.) 5, Risk factors for NAFLD; 2016. Available from: https://www.ncbi.nlm.nih.gov/books/NBK384735/.", "ArticleIdList": ["27441333"]}, {"Citation": "Lau E, Carvalho D, Freitas P. Gut microbiota: association with NAFLD and metabolic disturbances. Biomed Res Int. 2015; Article ID 979515. 9 pages. doi:10.1155/2015/979515.", "ArticleIdList": ["PMC4452311", "26090468"]}, {"Citation": "Camps J, Marsillach J, Rull A, Alonso-Villaverde C, Joven J. Interrelationships between paraoxonase-1 and monocyte chemoattractant protein-1 in the regulation of hepatic inflammation. Adv Exp Med Biol. 2010;660:5\u201318. doi: 10.1007/978-1-60761-350-3_2.", "ArticleIdList": ["10.1007/978-1-60761-350-3_2", "20221866"]}, {"Citation": "Atamer A, Bilici A, Yenice N, Selek S, Ilhan N, Atamer Y. The importance of paraoxonase 1 activity, nitric oxide and lipid peroxidation in hepatosteatosis. J Int Med Res. 2008;36:771\u20136. doi: 10.1177/147323000803600419.", "ArticleIdList": ["10.1177/147323000803600419", "18652773"]}, {"Citation": "Khateeb J, Gantman A, Kreitenberg AJ, Aviram M, Fuhrman B. Paraoxonase 1 (PON1) expression in hepatocytes is upregulated by pomegranate polyphenols: a role for PPAR-gamma pathway. Atherosclerosis. 2010;208(1):119\u201325. doi: 10.1016/j.atherosclerosis.2009.08.051.", "ArticleIdList": ["10.1016/j.atherosclerosis.2009.08.051", "19783251"]}, {"Citation": "Yoon JH, Baek SJ. Molecular targets of dietary polyphenols with anti-inflammatory properties. Yonsei Med J. 2005;46(5):585\u201396. doi: 10.3349/ymj.2005.46.5.585.", "ArticleIdList": ["10.3349/ymj.2005.46.5.585", "PMC2562783", "16259055"]}, {"Citation": "Santangelo C, Var\u00ec R, Scazzocchio B, Benedetto RD, Filesi C, Masella R. Polyphenols, intracellular signalling and inflammation. Ann Ist Super Sanita. 2007;43(4):394\u2013405.", "ArticleIdList": ["18209273"]}, {"Citation": "Penumetcha M and Santanam. Nutraceuticals as ligands of PPAR\u03b3. PPAR Research. 2012:1\u20137. Article ID 858352. doi:10.1155/2012/858352.", "ArticleIdList": ["PMC3388323", "22792089"]}, {"Citation": "Park MJ, Kim DI, Choi JH, Heo YR, Park SH. New role of irisin in hepatocytes: the protective effect of hepatic steatosis in vitro. Cell Signal. 2015", "ArticleIdList": ["25917316"]}, {"Citation": "Gamas L, Matafome P, Sei\u00e7a R. Irisin and myonectin regulation in the insulin resistant muscle: implications to adipose tissue: muscle crosstalk. J Diabetes Res. 2015:8. Article ID 359159. doi:10.1155/2015/359159.", "ArticleIdList": ["PMC4436512", "26075283"]}, {"Citation": "Panati K, Suneetha Y, Narala VR. Irisin/FNDC5\u2014An updated review. Eur Rev Med Pharmacol Sci. 2016;20:689\u201397.", "ArticleIdList": ["26957272"]}, {"Citation": "Sanchis-Gomar F, Perez-Quilis C. The p38\u2013PGC-1\u03b1\u2013irisin\u2013betatrophin axis. Adipocyte. 2014;3(1):67\u20138. doi: 10.4161/adip.27370.", "ArticleIdList": ["10.4161/adip.27370", "PMC3917937", "24575373"]}, {"Citation": "Arias-Loste MT, Ranchal I, Romero-G\u00f3mez M, Crespo J. Irisin, a link among fatty liver disease, physical inactivity and insulin resistance. Int J Mol Sci. 2014;15:23163\u201378. doi: 10.3390/ijms151223163.", "ArticleIdList": ["10.3390/ijms151223163", "PMC4284758", "25514415"]}, {"Citation": "Chen JQ, Huang YY, Gusdon AM, Qu S. Irisin: a new molecular marker and target in metabolic disorder. Lipids Health Dis. 2015;14(1):2\u20136. doi: 10.1186/1476-511X-14-2.", "ArticleIdList": ["10.1186/1476-511X-14-2", "PMC4417264", "25588692"]}, {"Citation": "Saleh BO, Majeed MJ, Oreaby GM. Irisin peptide is myokine, anti-obesity and anti-lipidemic factor. Am J Res Comput. 2015;3(1):20\u201330."}, {"Citation": "Bluher S, Panagiotou G, Petroff D, Markert J, Wagner A, Klemm T, et al. Effects of a 1-year exercise and lifestyle intervention on irisin, adipokines, and inflammatory markers in obese children. Obesity. 2014", "ArticleIdList": ["24644099"]}, {"Citation": "Zhang HJ, Zhang XF, Ma ZM, Pan LL, Chen Z, Han HW, et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. J Hepatol. 2013;59:557\u201362. doi: 10.1016/j.jhep.2013.04.030.", "ArticleIdList": ["10.1016/j.jhep.2013.04.030", "23665283"]}, {"Citation": "Salminena A, Kaarniranta K, Kauppinenc A. Crosstalk between oxidative stress and SIRT1: impact on the aging process. Int J Mol Sci. 2013;14:3834\u201359. doi: 10.3390/ijms14023834.", "ArticleIdList": ["10.3390/ijms14023834", "PMC3588074", "23434668"]}, {"Citation": "Elliott PJ, Jirousek M. Sirtuins: novel targets for metabolic disease. Curr Opin Investig Drugs. 2008;9(4):371\u20138.", "ArticleIdList": ["18393104"]}, {"Citation": "Chung S, Yao H, Caito S, Hwang J, Arunachalam G, Rahman I. Regulation of SIRT1 in cellular functions: role of polyphenols. Arch Biochem Biophys. 2010;501:79\u201390. doi: 10.1016/j.abb.2010.05.003.", "ArticleIdList": ["10.1016/j.abb.2010.05.003", "PMC2930135", "20450879"]}, {"Citation": "Farris PK. Innovative cosmeceuticals: sirtuin activators and anti-glycation compounds. Semin Cutan Med Surg. 2011;30:163\u20136. doi: 10.1016/j.sder.2011.05.004.", "ArticleIdList": ["10.1016/j.sder.2011.05.004", "21925370"]}, {"Citation": "Salminena A, Kauppinenc A, Kaarniranta K. Phytochemicals suppress nuclear factor-kB signaling: impact on health span and the aging process. Curr Opin Clin Nutr Metab Care. 2012;15(1):23\u20138. doi: 10.1097/MCO.0b013e32834d3ae7.", "ArticleIdList": ["10.1097/MCO.0b013e32834d3ae7", "22108095"]}, {"Citation": "Han X, Shen T, Lou H. Dietary polyphenols and their biological significance. Int J Mol Sci. 2007;8:950\u201388. doi: 10.3390/i8090950.", "ArticleIdList": ["10.3390/i8090950"]}, {"Citation": "Brglez Mojzer E, Knez Hrn\u010di\u010d M, \u0160kerget M, Knez \u017d, Bren U. Polyphenols: extraction methods, antioxidative action, bioavailability and anticarcinogenic effects. Molecules. 2016;21(7):901. doi: 10.3390/molecules21070901.", "ArticleIdList": ["10.3390/molecules21070901", "PMC6273793", "27409600"]}, {"Citation": "Kim JA, Kim DK, Kang OH, Choi YA, Park HJ, Choi SC, Kim TH, Yun KJ, Nah YH, Lee YM. Inhibitory effect of luteolin on TNF-\u03b1-induced IL-8 production in human colon epithelial cells. Int Immunopharmacol. 2005;5(1):209\u201317. doi: 10.1016/j.intimp.2004.09.027.", "ArticleIdList": ["10.1016/j.intimp.2004.09.027", "15589482"]}, {"Citation": "H\u00e4m\u00e4l\u00e4inen M, Nieminen R, Vuorela P, Heinonen M, Moilanen E. Anti-inflammatory effects of flavonoids: genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF-kappaB activations, whereas flavone, isorhamnetin, naringeninand pelargonidin inhibit only NF-kappaBactivation along with their inhibitory effect on iNOS expression and NO production in activated macrophages. Mediators Inflamm. 2007;2007:Article ID 45673. doi: 10.1155/2007/45673.", "ArticleIdList": ["10.1155/2007/45673", "PMC2220047", "18274639"]}, {"Citation": "Kim HK, Park HR, Lee JS, Chung TS, Chung HY, Chung J. Down-regulation of iNOS and TNF-alpha expression by kaempferol via NF-kappaB inactivation in aged rats gingival tissues. Biogerontology. 2007;8(4):399\u2013408. doi: 10.1007/s10522-007-9083-9.", "ArticleIdList": ["10.1007/s10522-007-9083-9", "17278014"]}, {"Citation": "Davis JM, Murphy EA, Martin DC. Effects of the dietary flavonoid quercetin upon performance and health. Curr Sports Med Rep. 2009;8(4):206\u201313. doi: 10.1249/JSR.0b013e3181ae8959.", "ArticleIdList": ["10.1249/JSR.0b013e3181ae8959", "19584608"]}, {"Citation": "Da-Silva WS, Harney JW, Kim BW, Li J, Bianco SD, Crescenzi A, Christoffolete MA, Huang SA, Bianco AC. The small polyphenolic molecule kaempferol increases cellular energy expenditure and thyroid hormone activation. Diabetes. 2007;56(3):767\u201376. doi: 10.2337/db06-1488.", "ArticleIdList": ["10.2337/db06-1488", "17327447"]}, {"Citation": "Dixon JB, Bhathal PS, Hughes NR, O\u2019Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology. 2004;39:1647\u201354. doi: 10.1002/hep.20251.", "ArticleIdList": ["10.1002/hep.20251", "15185306"]}, {"Citation": "Luyckx FH, Desaive C, Thiry A, Dewe W, Scheen AJ, Gielen JE, Lefebvre PJ. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord. 1998;22:222\u20136. doi: 10.1038/sj.ijo.0800571.", "ArticleIdList": ["10.1038/sj.ijo.0800571", "9539189"]}, {"Citation": "Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology. 1990;99:1408\u201313. doi: 10.1016/0016-5085(90)91169-7.", "ArticleIdList": ["10.1016/0016-5085(90)91169-7", "2210247"]}, {"Citation": "Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol. 1997;27:103\u20137. doi: 10.1016/S0168-8278(97)80287-5.", "ArticleIdList": ["10.1016/S0168-8278(97)80287-5", "9252081"]}, {"Citation": "Shah K, Stufflebam A, Hilton TN, Sinacore DR, Klein S, Villareal DT. Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults. Obesity. 2009;17:2162\u20138. doi: 10.1038/oby.2009.126.", "ArticleIdList": ["10.1038/oby.2009.126", "PMC2793412", "19390517"]}, {"Citation": "Katan MB. Weight-loss diets for the prevention and treatment of obesity. N Engl J Med. 2009;360:923\u20135. doi: 10.1056/NEJMe0810291.", "ArticleIdList": ["10.1056/NEJMe0810291", "19246365"]}, {"Citation": "Zelber-Sagi S, Ratziu V, Oren R. Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol. 2011;17(29):3377\u201389. doi: 10.3748/wjg.v17.i29.3377.", "ArticleIdList": ["10.3748/wjg.v17.i29.3377", "PMC3160564", "21876630"]}, {"Citation": "Verma SK, Jain V, Katewa SS. Blood pressure lowering, fibrinolysis enhancing and antioxidant activities of cardamom (Elettaria cardamomum) Indian J Biochem Biophys. 2009;46:503\u20136.", "ArticleIdList": ["20361714"]}, {"Citation": "Vijayan KK, Madhusoodanan KJ, Radhakrishnan VV, Ravindran PN. Properties and end-uses of cardamom. In Cardamom. The genus Elettaria. Ravindran PN, Madhusoodanan KJ (eds.). London: Taylor & Francis; 2002;269\u2013283. https://books.google.com/books?hl=en&lr=&id=tnH1bFGKuRoC&oi=fnd&pg=PA269&dq=properties+and+end-uses+of+cardamom,+cardamom+the+genus+Elettaria.&ots=LXqh6C-OhR&sig=xAHCqPcaI_FX_cxWqxpK3o60k14#v=onepage&q=properties%20and%20end-uses%20of%20cardamom%2C%20cardamom%20the%20genus%20Elettaria.&f=false."}, {"Citation": "Suneetha WJ, Krishnakantha TP. Cardamom extract as inhibitor of human platelet aggregation. Phytother Res. 2005;19:437\u201340. doi: 10.1002/ptr.1681.", "ArticleIdList": ["10.1002/ptr.1681", "16106388"]}, {"Citation": "Aggarwal BB, Kunnumakkara AB. Molecular Targets and Therapeutic Uses of Spices - Modern Uses for Ancient Medicine. 430 p [Different chapters written by experts compiling therapeutic uses of spices of selected spices, fenugreek in the present case]. Singapore: World Scientific Publishing Co. Pvt. Ltd. pp. 65\u201385. https://books.google.com/books?id=xblX4RL_qQgC&q=65#v=snippet&q=65&f=false."}, {"Citation": "Ekhlasi G, Shidfar F, Agah S, Merat S, Hosseini KAF. Effect of pomegranate juice intake on lipid profile in patients with nonalcoholic fatty liver disease. Razi J Med Sci. 2013;20(111):30\u20139."}, {"Citation": "Musso G, Gambino R, Cassader M, Pagano G. A Meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010;52:79\u2013104. doi: 10.1002/hep.23623.", "ArticleIdList": ["10.1002/hep.23623", "20578268"]}, {"Citation": "Verma SK, Jain V, Singh DP. Effect of greater cardamom (Amomum subulatum Roxb.) on blood lipids, fibrinolysis and total antioxidant status in patients with ischemic heart disease. Asian Pacific J Trop Dis. 2012;2:S739\u201343. doi: 10.1016/S2222-1808(12)60255-2.", "ArticleIdList": ["10.1016/S2222-1808(12)60255-2"]}, {"Citation": "Natural Medicine Comprehensive Database (NMCD). http://www.naturaldatabase.com. Accessed 21 Aug 2012."}, {"Citation": "The lab tests online. Laboratory methods used for medical lab testing (enzyme-linked immunosorbent assay (ELISA)) [Internet]. 2012. [cited 26 Feb 2017]. Available from: https://labtestsonline.org/understanding/features/methods/start/2/. Accessed 26 Feb 2017."}, {"Citation": "Jazayeri S, Nouri M, Pour-Ebrahim R, Fakhrzadeh H, Larijani B. Food and nutrient intake status in urban population (20\u201360 years) of population research center of Tehran University of Medical Sciences. Iran J Diab Lipid. 2005;1(3):81\u20139."}, {"Citation": "Qaffarpour M, Houshyar-Rad A, Kianfar H. Guides of home scales, conversion coefficients and percentage of Iranian foods. Tehran: Agricultural Sciences Publication; 2000."}, {"Citation": "The IPAQ group. International Physical Activity Questionnaire [Internet]. 2017. [cited 26 Feb 2017]. Available from: https://sites.google.com/site/theipaq/."}, {"Citation": "Booth ML, Ainsworth BE, Pratt MI, Ekelund U, Yngve AG, Sallis JF, Oja PE. International Physical Activity Questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;195(9131/03):3508\u20131381.", "ArticleIdList": ["12900694"]}, {"Citation": "Dinger M, Behrens T, Han J. Validity and Reliability of the International Physical Activity Questionnaire in College Students. Am J Health Educ. 2006;37(6):337\u201343. doi: 10.1080/19325037.2006.10598924.", "ArticleIdList": ["10.1080/19325037.2006.10598924"]}, {"Citation": "Lee PH, Macfarlane DJ, Lam TH, Stewart SM. Validity of the International Physical Activity Questionnaire short form (IPAQ-SF): a systematic review. Int J Behav Nutr Phys Act. 2011;8:115. doi: 10.1186/1479-5868-8-115.", "ArticleIdList": ["10.1186/1479-5868-8-115", "PMC3214824", "22018588"]}, {"Citation": "Vafai-Najar A, Vahedian-Shahroodi M, Tehrani H, Dogonchi M, Lael-Monfared E. The effectiveness of physical activity training on depersonalization of employees. Iran J Health Educ Health Promot. 2015;3(2):116\u201324."}, {"Citation": "Baghiani-Moghaddam MH, Bakhtari-Aghdam F, Asghari-Jafarabadi M, Allahverdipour H, Saeed Dabagh-Nikookheslat S, Nourizadeh R. Comparing the results of pedometer-based data and International Physical Activity Questionnaire (IPAQ) J Health Syst Res. 2013;9(6):605\u201312."}]}], "History": [{"Year": "2016", "Month": "11", "Day": "28"}, {"Year": "2017", "Month": "5", "Day": "8"}, {"Year": "2017", "Month": "6", "Day": "9", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "6", "Day": "9", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "5", "Day": "17", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "6", "Day": "7"}], "PublicationStatus": "epublish", "ArticleIdList": ["28592311", "PMC5463368", "10.1186/s13063-017-1979-3", "10.1186/s13063-017-1979-3"]}}]}